Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ArithroMab
- Development stage
- Preclinical
- Lead developer
- MD Bioproducts
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ArithroMab is a specialized cocktail of monoclonal antibodies directed against type II collagen (CII), primarily used as a research tool to induce Collagen Antibody-Induced Arthritis (CAIA) in susceptible mouse strains. Developed by MD Bioproducts, this reagent allows researchers to bypass the lengthy immunization phase required by the traditional Collagen-Induced Arthritis (CIA) model, providing a rapid, synchronized, and highly reproducible model of the effector phase of rheumatoid arthritis. The cocktail typically consists of several monoclonal antibodies that recognize distinct epitopes within the C1 domain of CII, leading to immune complex formation, complement activation, and subsequent joint inflammation, edema, and bone erosion. It is widely utilized in preclinical studies to evaluate the efficacy of novel anti-inflammatory and analgesic compounds.
- Brand names
- ArithroMab
- Other names
- Collagen Antibody CocktailCAIA Cocktail
02
Targets
COL2 (Type II Collagen)
Beyond the preview
Go deeper on ArithroMab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ArithroMab.